Literature DB >> 14742541

Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Ghislaine Prévot1, Eliane Bourreau, Herve Pascalis, Roger Pradinaud, Audrey Tanghe, Kris Huygen, Pascal Launois.   

Abstract

Buruli disease, caused by Mycobacterium ulcerans, is the third most important mycobacterial disease in humans besides tuberculosis and leprosy. We have compared systemic and intralesional cytokine production in patients presenting with a nodular form and a necrotizing, ulcerative form of the disease. Gamma interferon (IFN-gamma) levels in response to whole M. ulcerans and Mycobacterium bovis BCG bacilli and in response to purified Ag85 protein from BCG were lower in peripheral blood mononuclear cells (PBMC) cultures from Buruli disease patients than in PBMC from healthy purified protein derivative-positive contacts. Interleukin-4 (IL-4) and IL-13 content was below the detection threshold in these PBMC cultures. IFN-gamma production after stimulation with M. ulcerans was significantly lower (P < 0.05) in PBMC cultures from patients with ulcers than in those from patients with nodules. On the other hand, PBMC from Buruli disease patients produced significant levels of IL-10 in response to M. ulcerans (but not to M. bovis BCG) and production was highest in patients with the ulcerative form. Third, semiquantitative reverse transcription-PCR analysis demonstrated a similar difference in the local, intralesional cytokine profile for the two forms of the disease: high IFN-gamma but low IL-10 mRNA levels in nodular lesions and high IL-10 but low IFN-gamma mRNA levels in ulcerative lesions. Intralesional IL-4 and IL-13 mRNA levels were low and only detected in patients with the ulcerative form. Our results indicate, although they do not formally prove, that production of IL-10 rather than production of IL-4 or IL-13 by Th2-type T cells may be involved in the low M. ulcerans-specific IFN-gamma response in Buruli disease patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742541      PMCID: PMC321599          DOI: 10.1128/IAI.72.2.958-965.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function.

Authors:  A A Pahlevan; D J Wright; C Andrews; K M George; P L Small; B M Foxwell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

2.  A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells.

Authors:  K M George; L Pascopella; D M Welty; P L Small
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12.

Authors:  E Bourreau; G Prévot; R Pradinaud; P Launois
Journal:  J Infect Dis       Date:  2001-02-09       Impact factor: 5.226

Review 4.  Mycobacterium ulcerans infection.

Authors:  T S van der Werf; W T van der Graaf; J W Tappero; K Asiedu
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

Review 5.  Mycobacterium ulcerans disease; Buruli ulcer.

Authors:  H S Thangaraj; M R Evans; M H Wansbrough-Jones
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

6.  Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.

Authors:  A Tanghe; J Content; J P Van Vooren; F Portaels; K Huygen
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Immune response to infection with Mycobacterium ulcerans.

Authors:  T M Gooding; P D Johnson; D E Campbell; J A Hayman; E L Hartland; A S Kemp; R M Robins-Browne
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Biochemical and genetic evidence for phospholipase C activity in Mycobacterium ulcerans.

Authors:  A Gomez; A Mve-Obiang; B Vray; J Remacle; K Chemlal; W M Meyers; F Portaels; P A Fonteyne
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Detection of phospholipase C in nontuberculous mycobacteria and its possible role in hemolytic activity.

Authors:  A Gomez; A Mve-Obiang; B Vray; W Rudnicka; I C Shamputa; F Portaels; W M Meyers; P A Fonteyne; L Realini
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts.

Authors:  Travis M Gooding; Paul D R Johnson; May Smith; Andrew S Kemp; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more
  27 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.

Authors:  Diana Diaz; Heinz Döbeli; Dorothy Yeboah-Manu; Ernestina Mensah-Quainoo; Arno Friedlein; Nicole Soder; Simona Rondini; Thomas Bodmer; Gerd Pluschke
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

3.  Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.

Authors:  Martinha S Oliveira; Alexandra G Fraga; Egídio Torrado; António G Castro; João P Pereira; Adhemar Longatto Filho; Fernanda Milanezi; Fernando C Schmitt; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

6.  Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas.

Authors:  R Hurtado Ortiz; D Aguilar Leon; H Orozco Estevez; A Martin; J Luna Herrera; L Flores Romo; F Portaels; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

7.  Family relationship, water contact and occurrence of Buruli ulcer in Benin.

Authors:  Ghislain Emmanuel Sopoh; Yves Thierry Barogui; Roch Christian Johnson; Ange Dodji Dossou; Michel Makoutodé; Sévérin Y Anagonou; Luc Kestens; Françoise Portaels
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

8.  The local immune response in ulcerative lesions of Buruli disease.

Authors:  A E Kiszewski; E Becerril; L D Aguilar; I T A Kader; W Myers; F Portaels; R Hernàndez Pando
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

9.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Authors:  R Phillips; C Horsfield; S Kuijper; S F Sarfo; J Obeng-Baah; S Etuaful; B Nyamekye; P Awuah; K M Nyarko; F Osei-Sarpong; S Lucas; A H J Kolk; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.